Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.
about
Medical treatments in the short term management of reflux oesophagitisMedical treatments in the short term management of reflux oesophagitisOmeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.pH, healing rate, and symptom relief in patients with GERD.Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolismIdentification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.Influence of acid secretory status on absorption of omeprazole from enteric coated granules.Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidineDouble blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring.Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients.The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.What is heartburn worth? A cost-utility analysis of management strategiesA rational approach to uninvestigated dyspepsia in primary care: review of the literature.Whither surgery in the treatment of gastroesophageal reflux disease (GERD)?Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretionA systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.The Indications, Applications, and Risks of Proton Pump InhibitorsComparative role of omeprazole in the treatment of gastroesophageal reflux disease.Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.The knife or the pill in the long-term treatment of gastroesophageal reflux disease?Histamine-2-receptor antagonists in gastro-oesophageal reflux.On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.Proton pump inhibitory therapy: then and now.Therapeutic progress--review XXXIII. Are we making progress in the drug treatment of oesophageal disease?Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.Acid suppression: how much is needed?Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.Acid and pepsin secretion in patients with esophagitis refractory to treatment with H2 antagonists.24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis.Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment.
P2860
Q24234225-98B3D3CD-8A8E-4757-B000-D590C9AF9DF5Q24245220-75A4327B-72EC-4C8D-9753-C687A49BE97EQ33624127-F9DC2F2B-5AAC-4470-A201-FA416D830A4AQ33898648-58130EB2-71EA-40B9-B4C5-4C7936758F47Q34345774-785B57C1-2CCC-4850-A70F-AC48281DF005Q34346434-2E5B54F5-65FF-4CC8-A611-4DAC1641E9D4Q34358008-E071EF66-97D1-407E-9A16-11DC1DD298EFQ34392389-C75B2C7D-80B0-49AB-A223-870484C224A6Q34392553-6FE9061A-E382-4A43-86E3-5052955BE53BQ34398323-41179EF8-E05C-4965-89A2-FC4B80C60E25Q34398436-32708024-46FC-4ABC-A0C6-E4A471EEEBD0Q34531831-D8552959-B01C-410A-94D0-F650C86483F3Q34541695-7EA79D39-CAE2-4439-A014-29EA8BE250F3Q34745082-1543314B-0AFA-48F8-A9A1-C7B25A179C1FQ35037626-F76AFD57-BEA9-47BC-95EE-DF999C8EC820Q35161878-D15A653A-9E1F-45EF-98BC-93DA45BAEB20Q35250682-4CEB77BD-FF99-4066-A700-4E2A9C13966FQ35364870-5FF40EA9-7C98-473F-ADE1-56FA7E59B062Q35745058-84804B50-CAC9-4C1E-85EB-5888E4066355Q36091187-8F36B0D4-1185-4EF0-AA1C-DA74F9D226A0Q36803997-87FD1A69-06B1-4547-A917-76E6F2F0C952Q36894058-375CBEA5-80A4-4C68-8A51-DA9BB5093B32Q36987502-CDAED383-D6B9-42B2-A5CA-A59AA95E05E6Q38367261-67B33E28-8DD8-4CCF-8128-430AE89E173BQ39438205-B31E2E2C-BE4C-45E5-BD02-AA3B4C7C20D3Q39466750-9EACC40D-69B2-4F90-87EA-9A0DDD89A1FBQ39567824-562D951F-CC98-47EA-AA45-08C0CE3AC4D6Q41560226-78A79BA0-E557-4C87-B37E-E945DDA055BCQ42002534-7F1A9327-81E7-4C90-B2DB-DB847C904176Q42471297-87A46F5F-89B9-4B5D-885B-FEE77CD0672AQ43173652-91D4064C-30EC-42F1-92FC-313E1C4925C6Q43188474-0CAA3801-814F-4883-8E5B-161B84589062Q43817651-473B14C4-7B88-4589-AA78-6C46DB9590F2Q43904274-E12205DE-DA60-45FE-A9CA-C2F3FEADF1E6Q44667066-8A5F9F73-A4A3-40E6-8C7A-4BEF76BC7D4CQ46534902-A0F487B8-F86A-4410-AE56-A4C5A0D1E787Q47919662-B3743E4A-B43C-40DF-8A4E-FBD7996628CCQ51605321-31C0FB4F-1001-4375-A7A0-69AA4A8B90DCQ51610740-D5905A65-9CB2-4A52-8B71-C40CF67A109FQ51623608-D2369F73-1AC9-4213-AE14-7F6A436F21F1
P2860
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Double-blind multicentre compa ...... atment of reflux oesophagitis.
@en
type
label
Double-blind multicentre compa ...... atment of reflux oesophagitis.
@en
prefLabel
Double-blind multicentre compa ...... atment of reflux oesophagitis.
@en
P2093
P1433
P1476
Double-blind multicentre compa ...... atment of reflux oesophagitis.
@en
P2093
C B Lamers
E C Klinkenberg-Knol
H P Festen
J M Jansen
S G Meuwissen
P304
P356
10.1016/S0140-6736(87)91726-0
P407
P577
1987-02-01T00:00:00Z